274 related articles for article (PubMed ID: 20950256)
1. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients.
Rosario PW; Xavier AC; Calsolari MR
Thyroid; 2010 Nov; 20(11):1247-52. PubMed ID: 20950256
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
[TBL] [Abstract][Full Text] [Related]
3. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
4. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
5. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
7. Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal.
Vallejo Casas JA; Mena Bares LM; Gálvez Moreno MA; Moreno Ortega E; Marlowe RJ; Maza Muret FR; Albalá González MD
Q J Nucl Med Mol Imaging; 2016 Jun; 60(2):163-71. PubMed ID: 26563902
[TBL] [Abstract][Full Text] [Related]
8. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
[TBL] [Abstract][Full Text] [Related]
9. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients.
Rosario PW; Xavier AC
Am J Clin Oncol; 2012 Apr; 35(2):101-4. PubMed ID: 21297429
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
[TBL] [Abstract][Full Text] [Related]
13. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence.
Rosario PW; Xavier AC; Calsolari MR
Thyroid; 2011 Jan; 21(1):49-53. PubMed ID: 20954820
[TBL] [Abstract][Full Text] [Related]
14. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
Rosario PW; Mourão GF; Calsolari MR
Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
[TBL] [Abstract][Full Text] [Related]
19. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
20. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
